| 1 | months | 101,692 |
| 2 | times/week | 153 |
| 3 | times/d | 26 |
| 4 | cycles/degree | 13 |
| 5 | sq-hdm | 12 |
| 6 | mg.kg-1.hr-1 | 9 |
| 7 | times/h | 7 |
| 8 | glu-ocn | 6 |
| 9 | d·wk-1 | 5 |
| 10 | micrograms/kg/h | 5 |
| 11 | months/pr | 5 |
| 12 | d.wk | 4 |
| 13 | mwtd | 4 |
| 14 | beta-hydroxycortisol | 3 |
| 15 | burst/min | 3 |
| 16 | days/cm | 3 |
| 17 | ml/mn | 3 |
| 18 | months-was | 3 |
| 19 | months/no | 3 |
| 20 | mumols/hr | 3 |
| 21 | sub-domains | 3 |
| 22 | treatments/week | 3 |
| 23 | dots/m | 2 |
| 24 | g/24-hour | 2 |
| 25 | hdda | 2 |
| 26 | months-of-age | 2 |
| 27 | moxa-cones | 2 |
| 28 | ng/mgdwt | 2 |
| 29 | week-treatment | 2 |
| 30 | wk. | 2 |
| 31 | µma | 2 |
| 32 | α,23,24,25-tetraol-16 | 2 |
| 33 | -fluvastatin | 1 |
| 34 | -years | 1 |
| 35 | 0⩽x⩽1 | 1 |
| 36 | 24/28-week | 1 |
| 37 | 251.84 | 1 |
| 38 | 253-b11 | 1 |
| 39 | 293±351 | 1 |
| 40 | 59.1+/-6.3 | 1 |
| 41 | 665.3±2 | 1 |
| 42 | 667.3 | 1 |
| 43 | acetyl-don | 1 |
| 44 | aerodynamics-acoustic | 1 |
| 45 | affecteds | 1 |
| 46 | aids-cancers | 1 |
| 47 | alpha-21-dihydroxy-5 | 1 |
| 48 | alpha-androstanediol | 1 |
| 49 | alpha-diolglucuronide | 1 |
| 50 | anterior/anterolateral | 1 |
| 51 | anthracyclin-treated | 1 |
| 52 | areas- | 1 |
| 53 | areas/regions | 1 |
| 54 | autonomically-blocked | 1 |
| 55 | azfa | 1 |
| 56 | benveniste | 1 |
| 57 | beta-hydroxycompactin | 1 |
| 58 | beta-isodihydrocadambine | 1 |
| 59 | boluses/h | 1 |
| 60 | canals/tooth | 1 |
| 61 | chemotherapy-cycles | 1 |
| 62 | cholorophylls | 1 |
| 63 | cities-hanoi | 1 |
| 64 | cohn-iv-1-fractions | 1 |
| 65 | companies/institutions | 1 |
| 66 | completers/group | 1 |
| 67 | coronavirus-positive | 1 |
| 68 | countries-australia | 1 |
| 69 | criteria-severity | 1 |
| 70 | csbms/week | 1 |
| 71 | cycles/repetitions | 1 |
| 72 | days.week | 1 |
| 73 | dearing | 1 |
| 74 | deleted/full-length | 1 |
| 75 | derees | 1 |
| 76 | diplomates | 1 |
| 77 | dorso-anterior | 1 |
| 78 | endpoints-ffbf | 1 |
| 79 | eviscerations | 1 |
| 80 | examiner-pairs | 1 |
| 81 | f4ac | 1 |
| 82 | failures/2 | 1 |
| 83 | fog-l | 1 |
| 84 | foot-areas | 1 |
| 85 | g/a- | 1 |
| 86 | g/pack | 1 |
| 87 | gms/dl | 1 |
| 88 | gr/d.l | 1 |
| 89 | gy×4 | 1 |
| 90 | g·ewe | 1 |
| 91 | hemi-hepatectomy | 1 |
| 92 | hens/treatment | 1 |
| 93 | histiocytosarcoma | 1 |
| 94 | homokaryons | 1 |
| 95 | hta-induced | 1 |
| 96 | hydroxyisovalerylcarnitine | 1 |
| 97 | hypertransamin/asemia | 1 |
| 98 | hypertriglyceridemia/hypercholesterolemia | 1 |
| 99 | implants/animal | 1 |
| 100 | isocortical | 1 |
| 101 | kcal.kg-1.wk-1 | 1 |
| 102 | kinase-gamma | 1 |
| 103 | medications-dextroamphetamine | 1 |
| 104 | metabolins | 1 |
| 105 | mftscores | 1 |
| 106 | mg/ml•min/paclitaxel | 1 |
| 107 | mg/sachet | 1 |
| 108 | mglkg | 1 |
| 109 | mg∙min/ml | 1 |
| 110 | microcompounds | 1 |
| 111 | microg*hour/ml | 1 |
| 112 | micrograms/microliter | 1 |
| 113 | milliarcseconds | 1 |
| 114 | million/ui | 1 |
| 115 | minute-walk-distance | 1 |
| 116 | mitoses/mm | 1 |
| 117 | ml/bpm | 1 |
| 118 | ml/kg/b.w | 1 |
| 119 | mlxkg-1xmin-1 | 1 |
| 120 | mo. | 1 |
| 121 | mo.mean | 1 |
| 122 | moiths | 1 |
| 123 | molcules | 1 |
| 124 | monocameral | 1 |
| 125 | monosomy/bap1-mutation/eif1ax-wild-type | 1 |
| 126 | month-period | 1 |
| 127 | month-treatment | 1 |
| 128 | months,192 | 1 |
| 129 | months. | 1 |
| 130 | months.couples | 1 |
| 131 | months.fc | 1 |
| 132 | months.longer | 1 |
| 133 | months.none | 1 |
| 134 | months/cr/pr | 1 |
| 135 | months/cr/pr=8 | 1 |
| 136 | months:1 | 1 |
| 137 | months=3.1±0.7 | 1 |
| 138 | months=3.4±0.4 | 1 |
| 139 | monthspostpartum | 1 |
| 140 | mopfs | 1 |
| 141 | mos. | 1 |
| 142 | move™ | 1 |
| 143 | nanomoles/g/minute | 1 |
| 144 | nn/s | 1 |
| 145 | non-arb/acei-control | 1 |
| 146 | nonentored | 1 |
| 147 | outcomes-frequency | 1 |
| 148 | pack-yrs | 1 |
| 149 | pancreas/others | 1 |
| 150 | pndors | 1 |
| 151 | post-pgf | 1 |
| 152 | pullets/cage | 1 |
| 153 | rats-subset | 1 |
| 154 | rct’s | 1 |
| 155 | regencies | 1 |
| 156 | rhodophyta | 1 |
| 157 | ripm | 1 |
| 158 | s/point | 1 |
| 159 | samples/h | 1 |
| 160 | scbm/week | 1 |
| 161 | scores-css | 1 |
| 162 | scores/episode | 1 |
| 163 | sec. | 1 |
| 164 | self-withdrew | 1 |
| 165 | sensoryneuropathy | 1 |
| 166 | sessions·week | 1 |
| 167 | sikhs | 1 |
| 168 | soft-gels | 1 |
| 169 | specimes | 1 |
| 170 | sponsor-administered | 1 |
| 171 | stent-free | 1 |
| 172 | stone-bearers | 1 |
| 173 | strain-mixture | 1 |
| 174 | studies.pooling | 1 |
| 175 | subj | 1 |
| 176 | tablets/die | 1 |
| 177 | three-year-periods | 1 |
| 178 | tigapuluh | 1 |
| 179 | times-daily | 1 |
| 180 | times.wk-1 | 1 |
| 181 | times/wk. | 1 |
| 182 | to-6-week | 1 |
| 183 | uti/patient/year | 1 |
| 184 | vmas | 1 |
| 185 | warships | 1 |
| 186 | water-in- | 1 |
| 187 | weaks | 1 |
| 188 | week-period | 1 |
| 189 | weekes | 1 |
| 190 | weeks-post-injection | 1 |
| 191 | weeks-regardless | 1 |
| 192 | weeks-respectively | 1 |
| 193 | weeks.2 | 1 |
| 194 | weeks.extended | 1 |
| 195 | weeks.this | 1 |
| 196 | weeks/subject | 1 |
| 197 | wk-rhgh | 1 |
| 198 | wk/diet | 1 |
| 199 | wood-units | 1 |
| 200 | year-dfs | 1 |
| 201 | year-old-children | 1 |
| 202 | year-os | 1 |
| 203 | years.generally | 1 |
| 204 | yeas | 1 |
| 205 | yeras | 1 |
| 206 | yr-follow-up | 1 |
| 207 | µ/kg/min | 1 |
| 208 | β-acetoxy-12 | 1 |
| 209 | β-hydroxy-erythrosuamate | 1 |
| 210 | μ-or | 1 |
| 1 | -fluvastatin | 1 |
| 2 | -years | 1 |
| 3 | 0⩽x⩽1 | 1 |
| 4 | 24/28-week | 1 |
| 5 | 251.84 | 1 |
| 6 | 253-b11 | 1 |
| 7 | 293±351 | 1 |
| 8 | 59.1+/-6.3 | 1 |
| 9 | 665.3±2 | 1 |
| 10 | 667.3 | 1 |
| 11 | acetyl-don | 1 |
| 12 | aerodynamics-acoustic | 1 |
| 13 | affecteds | 1 |
| 14 | aids-cancers | 1 |
| 15 | alpha-21-dihydroxy-5 | 1 |
| 16 | alpha-androstanediol | 1 |
| 17 | alpha-diolglucuronide | 1 |
| 18 | anterior/anterolateral | 1 |
| 19 | anthracyclin-treated | 1 |
| 20 | areas- | 1 |
| 21 | areas/regions | 1 |
| 22 | autonomically-blocked | 1 |
| 23 | azfa | 1 |
| 24 | benveniste | 1 |
| 25 | beta-hydroxycompactin | 1 |
| 26 | beta-hydroxycortisol | 3 |
| 27 | beta-isodihydrocadambine | 1 |
| 28 | boluses/h | 1 |
| 29 | burst/min | 3 |
| 30 | canals/tooth | 1 |
| 31 | chemotherapy-cycles | 1 |
| 32 | cholorophylls | 1 |
| 33 | cities-hanoi | 1 |
| 34 | cohn-iv-1-fractions | 1 |
| 35 | companies/institutions | 1 |
| 36 | completers/group | 1 |
| 37 | coronavirus-positive | 1 |
| 38 | countries-australia | 1 |
| 39 | criteria-severity | 1 |
| 40 | csbms/week | 1 |
| 41 | cycles/degree | 13 |
| 42 | cycles/repetitions | 1 |
| 43 | d.wk | 4 |
| 44 | days.week | 1 |
| 45 | days/cm | 3 |
| 46 | dearing | 1 |
| 47 | deleted/full-length | 1 |
| 48 | derees | 1 |
| 49 | diplomates | 1 |
| 50 | dorso-anterior | 1 |
| 51 | dots/m | 2 |
| 52 | d·wk-1 | 5 |
| 53 | endpoints-ffbf | 1 |
| 54 | eviscerations | 1 |
| 55 | examiner-pairs | 1 |
| 56 | f4ac | 1 |
| 57 | failures/2 | 1 |
| 58 | fog-l | 1 |
| 59 | foot-areas | 1 |
| 60 | g/24-hour | 2 |
| 61 | g/a- | 1 |
| 62 | g/pack | 1 |
| 63 | glu-ocn | 6 |
| 64 | gms/dl | 1 |
| 65 | gr/d.l | 1 |
| 66 | gy×4 | 1 |
| 67 | g·ewe | 1 |
| 68 | hdda | 2 |
| 69 | hemi-hepatectomy | 1 |
| 70 | hens/treatment | 1 |
| 71 | histiocytosarcoma | 1 |
| 72 | homokaryons | 1 |
| 73 | hta-induced | 1 |
| 74 | hydroxyisovalerylcarnitine | 1 |
| 75 | hypertransamin/asemia | 1 |
| 76 | hypertriglyceridemia/hypercholesterolemia | 1 |
| 77 | implants/animal | 1 |
| 78 | isocortical | 1 |
| 79 | kcal.kg-1.wk-1 | 1 |
| 80 | kinase-gamma | 1 |
| 81 | medications-dextroamphetamine | 1 |
| 82 | metabolins | 1 |
| 83 | mftscores | 1 |
| 84 | mg.kg-1.hr-1 | 9 |
| 85 | mg/ml•min/paclitaxel | 1 |
| 86 | mg/sachet | 1 |
| 87 | mglkg | 1 |
| 88 | mg∙min/ml | 1 |
| 89 | microcompounds | 1 |
| 90 | microg*hour/ml | 1 |
| 91 | micrograms/kg/h | 5 |
| 92 | micrograms/microliter | 1 |
| 93 | milliarcseconds | 1 |
| 94 | million/ui | 1 |
| 95 | minute-walk-distance | 1 |
| 96 | mitoses/mm | 1 |
| 97 | ml/bpm | 1 |
| 98 | ml/kg/b.w | 1 |
| 99 | ml/mn | 3 |
| 100 | mlxkg-1xmin-1 | 1 |
| 101 | mo. | 1 |
| 102 | mo.mean | 1 |
| 103 | moiths | 1 |
| 104 | molcules | 1 |
| 105 | monocameral | 1 |
| 106 | monosomy/bap1-mutation/eif1ax-wild-type | 1 |
| 107 | month-period | 1 |
| 108 | month-treatment | 1 |
| 109 | months | 101,692 |
| 110 | months,192 | 1 |
| 111 | months-of-age | 2 |
| 112 | months-was | 3 |
| 113 | months. | 1 |
| 114 | months.couples | 1 |
| 115 | months.fc | 1 |
| 116 | months.longer | 1 |
| 117 | months.none | 1 |
| 118 | months/cr/pr | 1 |
| 119 | months/cr/pr=8 | 1 |
| 120 | months/no | 3 |
| 121 | months/pr | 5 |
| 122 | months:1 | 1 |
| 123 | months=3.1±0.7 | 1 |
| 124 | months=3.4±0.4 | 1 |
| 125 | monthspostpartum | 1 |
| 126 | mopfs | 1 |
| 127 | mos. | 1 |
| 128 | move™ | 1 |
| 129 | moxa-cones | 2 |
| 130 | mumols/hr | 3 |
| 131 | mwtd | 4 |
| 132 | nanomoles/g/minute | 1 |
| 133 | ng/mgdwt | 2 |
| 134 | nn/s | 1 |
| 135 | non-arb/acei-control | 1 |
| 136 | nonentored | 1 |
| 137 | outcomes-frequency | 1 |
| 138 | pack-yrs | 1 |
| 139 | pancreas/others | 1 |
| 140 | pndors | 1 |
| 141 | post-pgf | 1 |
| 142 | pullets/cage | 1 |
| 143 | rats-subset | 1 |
| 144 | rct’s | 1 |
| 145 | regencies | 1 |
| 146 | rhodophyta | 1 |
| 147 | ripm | 1 |
| 148 | s/point | 1 |
| 149 | samples/h | 1 |
| 150 | scbm/week | 1 |
| 151 | scores-css | 1 |
| 152 | scores/episode | 1 |
| 153 | sec. | 1 |
| 154 | self-withdrew | 1 |
| 155 | sensoryneuropathy | 1 |
| 156 | sessions·week | 1 |
| 157 | sikhs | 1 |
| 158 | soft-gels | 1 |
| 159 | specimes | 1 |
| 160 | sponsor-administered | 1 |
| 161 | sq-hdm | 12 |
| 162 | stent-free | 1 |
| 163 | stone-bearers | 1 |
| 164 | strain-mixture | 1 |
| 165 | studies.pooling | 1 |
| 166 | sub-domains | 3 |
| 167 | subj | 1 |
| 168 | tablets/die | 1 |
| 169 | three-year-periods | 1 |
| 170 | tigapuluh | 1 |
| 171 | times-daily | 1 |
| 172 | times.wk-1 | 1 |
| 173 | times/d | 26 |
| 174 | times/h | 7 |
| 175 | times/week | 153 |
| 176 | times/wk. | 1 |
| 177 | to-6-week | 1 |
| 178 | treatments/week | 3 |
| 179 | uti/patient/year | 1 |
| 180 | vmas | 1 |
| 181 | warships | 1 |
| 182 | water-in- | 1 |
| 183 | weaks | 1 |
| 184 | week-period | 1 |
| 185 | week-treatment | 2 |
| 186 | weekes | 1 |
| 187 | weeks-post-injection | 1 |
| 188 | weeks-regardless | 1 |
| 189 | weeks-respectively | 1 |
| 190 | weeks.2 | 1 |
| 191 | weeks.extended | 1 |
| 192 | weeks.this | 1 |
| 193 | weeks/subject | 1 |
| 194 | wk-rhgh | 1 |
| 195 | wk. | 2 |
| 196 | wk/diet | 1 |
| 197 | wood-units | 1 |
| 198 | year-dfs | 1 |
| 199 | year-old-children | 1 |
| 200 | year-os | 1 |
| 201 | years.generally | 1 |
| 202 | yeas | 1 |
| 203 | yeras | 1 |
| 204 | yr-follow-up | 1 |
| 205 | µ/kg/min | 1 |
| 206 | µma | 2 |
| 207 | α,23,24,25-tetraol-16 | 2 |
| 208 | β-acetoxy-12 | 1 |
| 209 | β-hydroxy-erythrosuamate | 1 |
| 210 | μ-or | 1 |
| 1 | g/a- | 1 |
| 2 | water-in- | 1 |
| 3 | areas- | 1 |
| 4 | sec. | 1 |
| 5 | wk. | 2 |
| 6 | times/wk. | 1 |
| 7 | mo. | 1 |
| 8 | months. | 1 |
| 9 | mos. | 1 |
| 10 | kcal.kg-1.wk-1 | 1 |
| 11 | times.wk-1 | 1 |
| 12 | d·wk-1 | 5 |
| 13 | mlxkg-1xmin-1 | 1 |
| 14 | mg.kg-1.hr-1 | 9 |
| 15 | 253-b11 | 1 |
| 16 | 293±351 | 1 |
| 17 | months:1 | 1 |
| 18 | 0⩽x⩽1 | 1 |
| 19 | weeks.2 | 1 |
| 20 | failures/2 | 1 |
| 21 | β-acetoxy-12 | 1 |
| 22 | months,192 | 1 |
| 23 | 665.3±2 | 1 |
| 24 | 59.1+/-6.3 | 1 |
| 25 | 667.3 | 1 |
| 26 | months=3.4±0.4 | 1 |
| 27 | 251.84 | 1 |
| 28 | gy×4 | 1 |
| 29 | alpha-21-dihydroxy-5 | 1 |
| 30 | α,23,24,25-tetraol-16 | 2 |
| 31 | months=3.1±0.7 | 1 |
| 32 | months/cr/pr=8 | 1 |
| 33 | hdda | 2 |
| 34 | azfa | 1 |
| 35 | countries-australia | 1 |
| 36 | hypertriglyceridemia/hypercholesterolemia | 1 |
| 37 | hypertransamin/asemia | 1 |
| 38 | kinase-gamma | 1 |
| 39 | histiocytosarcoma | 1 |
| 40 | µma | 2 |
| 41 | rhodophyta | 1 |
| 42 | f4ac | 1 |
| 43 | months.fc | 1 |
| 44 | aerodynamics-acoustic | 1 |
| 45 | times/d | 26 |
| 46 | hta-induced | 1 |
| 47 | weeks.extended | 1 |
| 48 | autonomically-blocked | 1 |
| 49 | sponsor-administered | 1 |
| 50 | nonentored | 1 |
| 51 | anthracyclin-treated | 1 |
| 52 | month-period | 1 |
| 53 | week-period | 1 |
| 54 | mwtd | 4 |
| 55 | minute-walk-distance | 1 |
| 56 | alpha-diolglucuronide | 1 |
| 57 | scores/episode | 1 |
| 58 | stent-free | 1 |
| 59 | cycles/degree | 13 |
| 60 | months-of-age | 2 |
| 61 | pullets/cage | 1 |
| 62 | tablets/die | 1 |
| 63 | beta-isodihydrocadambine | 1 |
| 64 | medications-dextroamphetamine | 1 |
| 65 | hydroxyisovalerylcarnitine | 1 |
| 66 | months.none | 1 |
| 67 | monosomy/bap1-mutation/eif1ax-wild-type | 1 |
| 68 | strain-mixture | 1 |
| 69 | β-hydroxy-erythrosuamate | 1 |
| 70 | benveniste | 1 |
| 71 | nanomoles/g/minute | 1 |
| 72 | coronavirus-positive | 1 |
| 73 | g·ewe | 1 |
| 74 | endpoints-ffbf | 1 |
| 75 | post-pgf | 1 |
| 76 | mglkg | 1 |
| 77 | studies.pooling | 1 |
| 78 | dearing | 1 |
| 79 | micrograms/kg/h | 5 |
| 80 | samples/h | 1 |
| 81 | times/h | 7 |
| 82 | boluses/h | 1 |
| 83 | wk-rhgh | 1 |
| 84 | deleted/full-length | 1 |
| 85 | canals/tooth | 1 |
| 86 | tigapuluh | 1 |
| 87 | cities-hanoi | 1 |
| 88 | million/ui | 1 |
| 89 | subj | 1 |
| 90 | g/pack | 1 |
| 91 | to-6-week | 1 |
| 92 | 24/28-week | 1 |
| 93 | days.week | 1 |
| 94 | scbm/week | 1 |
| 95 | times/week | 153 |
| 96 | csbms/week | 1 |
| 97 | treatments/week | 3 |
| 98 | sessions·week | 1 |
| 99 | d.wk | 4 |
| 100 | fog-l | 1 |
| 101 | gr/d.l | 1 |
| 102 | isocortical | 1 |
| 103 | implants/animal | 1 |
| 104 | monocameral | 1 |
| 105 | anterior/anterolateral | 1 |
| 106 | gms/dl | 1 |
| 107 | mg/ml•min/paclitaxel | 1 |
| 108 | mg∙min/ml | 1 |
| 109 | microg*hour/ml | 1 |
| 110 | alpha-androstanediol | 1 |
| 111 | non-arb/acei-control | 1 |
| 112 | beta-hydroxycortisol | 3 |
| 113 | dots/m | 2 |
| 114 | days/cm | 3 |
| 115 | sq-hdm | 12 |
| 116 | mitoses/mm | 1 |
| 117 | ml/bpm | 1 |
| 118 | ripm | 1 |
| 119 | monthspostpartum | 1 |
| 120 | mo.mean | 1 |
| 121 | glu-ocn | 6 |
| 122 | year-old-children | 1 |
| 123 | µ/kg/min | 1 |
| 124 | burst/min | 3 |
| 125 | -fluvastatin | 1 |
| 126 | beta-hydroxycompactin | 1 |
| 127 | ml/mn | 3 |
| 128 | acetyl-don | 1 |
| 129 | weeks-post-injection | 1 |
| 130 | months/no | 3 |
| 131 | yr-follow-up | 1 |
| 132 | completers/group | 1 |
| 133 | uti/patient/year | 1 |
| 134 | months.longer | 1 |
| 135 | micrograms/microliter | 1 |
| 136 | mumols/hr | 3 |
| 137 | μ-or | 1 |
| 138 | dorso-anterior | 1 |
| 139 | months/cr/pr | 1 |
| 140 | months/pr | 5 |
| 141 | g/24-hour | 2 |
| 142 | nn/s | 1 |
| 143 | foot-areas | 1 |
| 144 | yeas | 1 |
| 145 | vmas | 1 |
| 146 | yeras | 1 |
| 147 | months-was | 3 |
| 148 | affecteds | 1 |
| 149 | milliarcseconds | 1 |
| 150 | microcompounds | 1 |
| 151 | three-year-periods | 1 |
| 152 | derees | 1 |
| 153 | regencies | 1 |
| 154 | weekes | 1 |
| 155 | chemotherapy-cycles | 1 |
| 156 | months.couples | 1 |
| 157 | molcules | 1 |
| 158 | specimes | 1 |
| 159 | moxa-cones | 2 |
| 160 | mftscores | 1 |
| 161 | diplomates | 1 |
| 162 | year-dfs | 1 |
| 163 | mopfs | 1 |
| 164 | sikhs | 1 |
| 165 | moiths | 1 |
| 166 | months | 101,692 |
| 167 | weeks.this | 1 |
| 168 | weaks | 1 |
| 169 | soft-gels | 1 |
| 170 | cholorophylls | 1 |
| 171 | sub-domains | 3 |
| 172 | metabolins | 1 |
| 173 | areas/regions | 1 |
| 174 | eviscerations | 1 |
| 175 | cohn-iv-1-fractions | 1 |
| 176 | cycles/repetitions | 1 |
| 177 | companies/institutions | 1 |
| 178 | homokaryons | 1 |
| 179 | year-os | 1 |
| 180 | warships | 1 |
| 181 | -years | 1 |
| 182 | aids-cancers | 1 |
| 183 | pancreas/others | 1 |
| 184 | stone-bearers | 1 |
| 185 | examiner-pairs | 1 |
| 186 | pndors | 1 |
| 187 | pack-yrs | 1 |
| 188 | scores-css | 1 |
| 189 | weeks-regardless | 1 |
| 190 | wood-units | 1 |
| 191 | rct’s | 1 |
| 192 | weeks/subject | 1 |
| 193 | mg/sachet | 1 |
| 194 | wk/diet | 1 |
| 195 | rats-subset | 1 |
| 196 | month-treatment | 1 |
| 197 | week-treatment | 2 |
| 198 | hens/treatment | 1 |
| 199 | s/point | 1 |
| 200 | ng/mgdwt | 2 |
| 201 | ml/kg/b.w | 1 |
| 202 | self-withdrew | 1 |
| 203 | outcomes-frequency | 1 |
| 204 | sensoryneuropathy | 1 |
| 205 | weeks-respectively | 1 |
| 206 | times-daily | 1 |
| 207 | years.generally | 1 |
| 208 | hemi-hepatectomy | 1 |
| 209 | criteria-severity | 1 |
| 210 | move™ | 1 |